Where clinical delivery infrastructure meets deep insights.
Current Health to invest in coordinating in-home staffing, services. Read the announcement.
Current Health to invest in coordinating in-home staffing, services. Read the announcement.
Accelerate your advanced therapy clinical trials and commercial expansion with virtual and in-home care models that extend access beyond AMCs. We operationalize safe outpatient and community-based treatment delivery across the therapy lifecycle.
We partner with leading manufacturers to move advanced therapies—including CAR-T and bispecifics—safely into outpatient and community settings.
By embedding early in clinical development, we generate RWE and build the clinical and operational infrastructure to accelerates approval, support payer negotiations, and enable scaled community and outpatient adoption.
Pharmacovigilance infrastructure in Phase I-III trials
RWE supports streamlined approvals, especially for ambulatory settings
RWE feeds payer negotiations; infrastructure enables community delivery
Scaled access through our provider network; optimized outcomes for all stakeholders
80% of advanced therapy revenue opportunity is in community settings. Our infrastructure enables delivery beyond urban AMCs, dramatically expanding your addressable market.
Remove friction for providers with turnkey monitoring, clinical support, and payer negotiation. Make it easy for more sites to adopt your therapy.
Continuous biometric monitoring creates rich datasets for safety profiling, outcomes research, and payer negotiations. Build the evidence base for value-based contracting.
24/7 nursing support through our Clinical Command Center removes the pressure from participants and caregivers to manually check for toxicities
In addition to monitoring, our team handles ICANS assessments, participant engagement, and logistics. We serve as the first-line of support for all questions and concerns.
Trial data demonstrating ambulatory safety can support FDA labeling for outpatient settings. Example: early dexamethasone protocols demonstrating lower CRS rates.
Lower total treatment cost through ambulatory delivery. Support payer negotiations with demonstrated safety and cost efficiency data.
Deep partnerships with leading health systems and community practices. Your brand visibility as a leader in patient access and innovation.
FDA Class II 510(k) for our platform and wearable
EU Class IIa CE-Marked for European approval
SOC 2, ISO 27001, ISO 13485 for security and quality
We’ve supported 15+ major global trials (Phase I-IV) with oversight of 12,000+ participants across the US, EU, and LATAM.
Pharmacovigilance monitoring in Phase I-IV
Safety biomarker development
Protocol co-development
EDC integration and data capture
Decentralized trial enablement
Provider network development and site activation support
Community adoption programs
Payer negotiation support
RWE generation for contracting
Ongoing safety and outcomes monitoring
The largest worldwide biometric dataset for outpatient advanced therapy delivery—enabling continuous improvement, biomarker development, and payer negotiations.
Of any clinical platform, combining continuous biometric data with detailed CRS and ICANS event characterization.
Rich datasets for training AI models and developing digital biomarkers for early adverse event detection.
Leading the science of ambulatory advanced therapy delivery with research partners at top institutions.
Where clinical delivery infrastructure meets deep insights.
Global clinical trial participants
CAR-T patients cared for, growing quickly
